Trial Profile

A Phase 2, Single-Arm Study to Evaluate PRS-343 in Combination with Ramucirumab and Paclitaxel in Second-Line Gastric Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 21 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cinrebafusp alfa (Primary) ; Paclitaxel (Primary) ; Ramucirumab (Primary)
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Proof of concept; Therapeutic Use
Sponsors Pieris Pharmaceuticals

Most Recent Events

13 Apr 2022 As per the Trial design, recruitment is ongoing and Approximately 10 sites in 3 countries in US, Asia and Europe are expected to participate.
13 Apr 2022 Status changed from planning to recruiting, according to trial design presented at the 113th Annual Meeting of the American Association for Cancer Research.
13 Apr 2022 Trial design presented at the 113th Annual Meeting of the American Association for Cancer Research.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com